Rep. Gilbert Ray Cisneros, Jr. Sells Shares of Revvity Inc. (NYSE:RVTY)

Key Points

• Rep. Gilbert Cisneros sold $1,001–$15,000 of Revvity shares on September 3. He also recently bought Benchmark Electronics and several healthcare-related stocks while selling positions including Oxford Industries, Semtech, ITT and BridgeBio Pharma.
• Revvity reported quarterly EPS of $1.41, beating estimates of $1.21, while revenue of $729.69 million exceeded expectations. However, revenue declined 1.3% year over year, and the company projected fiscal 2026 EPS of $5.30–$5.40.
• RVTY opened at $155.08, near its 12-month high, while analysts maintain a consensus “Hold” rating with a $124.43 target price. The company declared a $0.07 quarterly dividend, and insiders have sold roughly $1.29 million of stock over the past three months.

Representative Gilbert Ray Cisneros, Jr. (Democratic-California) recently sold shares of Revvity Inc. NYSE: RVTY. In a filing disclosed on October 12th, the Representative disclosed that they had sold between $1,001 and $15,000 in Revvity stock on September 3rd.

Representative Gilbert Ray Cisneros, Jr. also recently made the following trade(s):

• Purchased $15,001 - $50,000 in shares of Benchmark Electronics NYSE: BHE on 10/1/2026.
• Sold $1,001 - $15,000 in shares of Oxford Industries NYSE: OXM on 9/29/2026.
• Sold $1,001 - $15,000 in shares of Semtech NASDAQ: SMTC on 9/29/2026.
• Sold $15,001 - $50,000 in shares of ITT NYSE: ITT on 9/29/2026.
• Sold $1,001 - $15,000 in shares of BridgeBio Pharma NASDAQ: BBIO on 9/29/2026.
• Purchased $1,001 - $15,000 in shares of Tandem Diabetes Care NASDAQ: TNDM on 9/29/2026.
• Purchased $1,001 - $15,000 in shares of Cytokinetics NASDAQ: CYTK on 9/29/2026.
• Purchased $1,001 - $15,000 in shares of Ultragenyx Pharmaceutical NASDAQ: RARE on 9/29/2026.
• Purchased $1,001 - $15,000 in shares of YETI NYSE: YETI on 9/29/2026.
• Sold $1,001 - $15,000 in shares of AtriCure NASDAQ: ATRC on 9/29/2026.

Revvity Price Performance

Revvity stock opened at $155.08 on Wednesday. The stock has a market cap of $17.31 billion, a P/E ratio of 73.85, a price-to-earnings-growth ratio of 2.83 and a beta of 1.06. The company has a fifty day simple moving average of $134.17 and a 200-day simple moving average of $112.19. Revvity Inc. has a 12-month low of $81.22 and a 12-month high of $166.25. The company has a current ratio of 1.80, a quick ratio of 1.50 and a debt-to-equity ratio of 0.36.

Revvity (NYSE:RVTY - Get Free Report) last posted its earnings results on Tuesday, August 4th. The company reported $1.41 EPS for the quarter, beating the consensus estimate of $1.21 by $0.20. The firm had revenue of $729.69 million for the quarter, compared to analyst estimates of $702.96 million. Revvity had a return on equity of 8.34% and a net margin of 8.16%. Revvity's revenue for the quarter was down 1.3% compared to the same quarter last year. During the same quarter in the prior year, the company posted $1.18 earnings per share. Revvity has set its FY 2026 guidance at 5.300-5.400 EPS. Equities analysts expect that Revvity Inc. will post 5.36 EPS for the current fiscal year.

Revvity Announces Dividend

The company also recently disclosed a quarterly dividend, which will be paid on Friday, November 13th. Stockholders of record on Friday, October 23rd will be given a dividend of $0.07 per share. This represents a $0.28 annualized dividend and a dividend yield of 0.2%. The ex-dividend date of this dividend is Friday, October 23rd. Revvity's payout ratio is 13.33%.

Insider Activity at Revvity

In other news, insider Tajinder S. Vohra sold 7,330 shares of Revvity stock in a transaction that occurred on Wednesday, September 16th. The shares were sold at an average price of $140.88, for a total transaction of $1,032,650.40. Following the sale, the insider owned 6,635 shares in the company, valued at $934,738.80. This trade represents a 52.49% decrease in their ownership of the stock. The transaction was disclosed in a document filed with the SEC, which is available at this hyperlink. Also, insider Maxwell Krakowiak sold 1,631 shares of the business's stock in a transaction on Monday, September 21st. The stock was sold at an average price of $144.53, for a total transaction of $235,728.43. Following the transaction, the insider directly owned 14,781 shares in the company, valued at approximately $2,136,297.93. The trade was a 9.94% decrease in their ownership of the stock. The SEC filing for this sale provides additional information. Insiders have sold a total of 9,130 shares of company stock worth $1,290,745 over the last three months. 0.85% of the stock is currently owned by corporate insiders.

Wall Street Analyst Weigh In

A number of analysts have weighed in on RVTY shares. Sanford C. Bernstein assumed coverage on shares of Revvity in a report on Friday, June 26th. They set a "market perform" rating and a $115.00 price objective on the stock. Evercore restated an "outperform" rating on shares of Revvity in a report on Wednesday, August 5th. Weiss Ratings raised shares of Revvity from a "hold (c-)" rating to a "hold (c)" rating in a research report on Thursday, October 8th. Wall Street Zen lowered shares of Revvity from a "buy" rating to a "hold" rating in a research note on Sunday, August 16th. Finally, Barclays lifted their price target on shares of Revvity from $115.00 to $160.00 and gave the stock an "equal weight" rating in a research note on Wednesday, October 7th. Five equities research analysts have rated the stock with a Buy rating and fourteen have given a Hold rating to the company's stock. According to MarketBeat.com, Revvity currently has an average rating of "Hold" and a consensus target price of $124.43.

Hedge Funds Weigh In On Revvity

A number of institutional investors have recently modified their holdings of the business. Northwestern Mutual Wealth Management Co. raised its position in Revvity by 5.4% in the second quarter. Northwestern Mutual Wealth Management Co. now owns 2,074 shares of the company's stock valued at $231,000 after purchasing an additional 106 shares during the period. EverSource Wealth Advisors LLC grew its stake in shares of Revvity by 17.0% in the first quarter. EverSource Wealth Advisors LLC now owns 749 shares of the company's stock valued at $66,000 after buying an additional 109 shares in the last quarter. Angeles Wealth Management LLC grew its stake in shares of Revvity by 2.0% in the second quarter. Angeles Wealth Management LLC now owns 5,804 shares of the company's stock valued at $646,000 after buying an additional 112 shares in the last quarter. Tema ETFs LLC raised its holdings in shares of Revvity by 8.1% during the 2nd quarter. Tema ETFs LLC now owns 1,946 shares of the company's stock valued at $217,000 after buying an additional 145 shares during the period. Finally, Glenmede Trust Co. NA raised its holdings in shares of Revvity by 4.0% during the 1st quarter. Glenmede Trust Co. NA now owns 4,696 shares of the company's stock valued at $411,000 after buying an additional 180 shares during the period. 86.65% of the stock is owned by institutional investors and hedge funds.

About Representative Cisneros

Gil Cisneros (Democratic Party) is a member of the U.S. House, representing California's 31st Congressional District. He assumed office on January 3, 2025. His current term ends on January 3, 2027. Cisneros (Democratic Party) is running for re-election to the U.S. House to represent California's 31st Congressional District. He declared candidacy for the 2026 election. Gil Cisneros served in the U.S. Navy as a supply officer from 1994 to 2004. Cisneros earned a bachelor's degree in political science from George Washington University in 1994, a master's in business administration from Regis University in 2002, and a master's degree in urban education policy from Brown University in 2015. His career experience includes working as a logistics manager for Frito-Lay. In 2010, Cisneros won the lottery and became involved in activism and philanthropy, founding a scholarship program for local high school students. In 2021, President Joe Biden (D) appointed Cisneros as under secretary of defense for personnel and readiness.

Revvity Company Profile

Revvity, Inc NYSE: RVTY is a life sciences and diagnostics company that provides technologies, products and services used in biological research, drug discovery, clinical testing and healthcare. The company serves pharmaceutical and biotechnology companies, academic and government research institutions, hospitals, clinical laboratories and other healthcare organizations.

Its portfolio includes instruments, reagents, consumables, software and related services for areas such as genomics, proteomics, cellular analysis, imaging and multiplex testing.

This instant news alert was generated by narrative science technology and financial data from MarketBeat in order to provide readers with the fastest reporting and unbiased coverage. Please send any questions or comments about this story to contact@marketbeat.com.